| Filed | Form | Description | |
|---|---|---|---|
| 11/12/25 | DEFA14A | DEFA14A | → |
| 10/14/25 | DEFA14A | DEFA14A | → |
| 10/14/25 | DEF 14A | DEF 14A | → |
| 11/14/24 | DEFA14A | DEFA14A | → |
| 10/22/24 | DEF 14A | DEF 14A | → |
| 10/22/24 | DEFA14A | DEFA14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 1/26/26 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | → |
| 12/29/25 | 4 | 4 | → |
| 12/22/25 | 4 | 4 | → |
| 12/3/25 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | → |
| 12/3/25 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | → |
| 12/3/25 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | → |
| ↓ | |||
Benitec Biopharma Limited is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.